STOK (Stoke Therapeutics) Cash per Share: $5.52 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STOK Stoke Therapeutics Inc STOK
45 GF Score
Price $29.32
GF Value $10.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Stoke Therapeutics Cash per Share?

Stoke Therapeutics STOK -1.26% 45 Cash per Share is $5.52 as of Mar. 2026. GuruFocus rates STOK with a GF Score™ of 45/100 and a GF Value™ of $10.05 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Stoke Therapeutics's Cash per Share for the quarter that ended in Mar. 2026 was $5.52.

Stoke Therapeutics  (NAS:STOK) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Stoke Therapeutics Cash per Share Related Terms

Stoke Therapeutics Cash per Share Historical Data

* Premium members only.

The historical data trend for Stoke Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stoke Therapeutics Cash per Share Chart

Stoke Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial Premium Member Only 5.96 5.82 4.39 4.01 4.83

Stoke Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.55 4.53 4.51 4.83 5.52
STOK
45GF Score
Stoke Therapeutics Inc STOK
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stoke Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Stoke Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=284.67/58.92
=4.83

Stoke Therapeutics's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=343.545/62.24
=5.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $5.52 mean?
Stoke Therapeutics (STOK) has a Cash per Share of $5.52 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Stoke Therapeutics and its competitors.
Is Stoke Therapeutics' Cash per Share too high?
Stoke Therapeutics' current Cash per Share is $5.52. Overall, Stoke Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' Cash per Share compare to TYRA and SNDX?
Stoke Therapeutics' Cash per Share of $5.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Stoke Therapeutics and its competitors. Stoke Therapeutics's current Cash per Share is $5.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (STOK) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.05, compared to a current price of $29.32 — trading 191.7% above its estimated fair value. The current Cash per Share is $5.52. Stoke Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Stoke Therapeutics (STOK), the current Cash per Share is $5.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stoke Therapeutics (STOK) Overvalued in 2026?

Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued. The current stock price of $29.32 is trading 191.7% above its estimated GF Value™ of $10.05. GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.

Key valuation signals for STOK:

  • Cash per Share: $5.52
  • GF Value™: $10.05 vs. price of $29.32 (191.7% above fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the STOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Stoke Therapeutics Business Description

Other Exchanges 0GT:Germany
Address 45 Wiggins Avenue, Bedford, MA, USA, 01730
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
45GF Score

Get the complete analysis for STOK

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.32
Price
$10.05
GF Value